Vistagen Therapeutics Stock Performance
| VTGN Stock | USD 2.79 0.02 0.72% |
On a scale of 0 to 100, VistaGen Therapeutics holds a performance score of 4. The entity has a beta of 0.65, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, VistaGen Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding VistaGen Therapeutics is expected to be smaller as well. Please check VistaGen Therapeutics' downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to make a quick decision on whether VistaGen Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in VistaGen Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, VistaGen Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.72 | Five Day Return 2.95 | Year To Date Return (15.96) | Ten Year Return (98.97) | All Time Return (99.81) |
Last Split Factor 1:30 | Last Split Date 2023-06-07 |
1 | Acquisition by Anderson Cynthia Lynn of 2592 shares of VistaGen Therapeutics at 2.5075 subject to Rule 16b-3 | 12/31/2024 |
2 | Acquisition by Smith Mark Alan of 5000 shares of VistaGen Therapeutics at 0.748 subject to Rule 16b-3 | 01/17/2025 |
3 | Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain | 02/05/2025 |
4 | Companies Like Vistagen Therapeutics Are In A Position To Invest In Growth | 02/12/2025 |
5 | VistaGen Therapeutics GAAP EPS of -0.46 beats by 0.05, revenue of 0.23M beats by 0.05M | 02/13/2025 |
6 | Vistagen Therapeutics Inc Q3 2025 Earnings Call Highlights Promising Trial Results and ... | 02/14/2025 |
7 | Acquisition by Dotson Jerrold Duane of 150000 shares of VistaGen Therapeutics at 1.37 subject to Rule 16b-3 | 02/18/2025 |
8 | Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference | 02/20/2025 |
9 | Is Vistagen Therapeutics In A Good Position To Invest In Growth | 02/28/2025 |
10 | Vistagen Therapeutics Inc Q3 FY2025 Earnings EPS of -0. - GuruFocus.com | 03/11/2025 |
11 | Vistagen Therapeutics Stock Price Crosses Above 50-Day Moving Average - Heres Why - MarketBeat | 03/21/2025 |
| Begin Period Cash Flow | 16.6 M |
VistaGen |
VistaGen Therapeutics Relative Risk vs. Return Landscape
If you would invest 255.00 in VistaGen Therapeutics on December 24, 2024 and sell it today you would earn a total of 24.00 from holding VistaGen Therapeutics or generate 9.41% return on investment over 90 days. VistaGen Therapeutics is currently generating 0.2086% in daily expected returns and assumes 3.5568% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than VistaGen, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
VistaGen Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VistaGen Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as VistaGen Therapeutics, and traders can use it to determine the average amount a VistaGen Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0587
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VTGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.56 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average VistaGen Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VistaGen Therapeutics by adding it to a well-diversified portfolio.
VistaGen Therapeutics Fundamentals Growth
VistaGen Stock prices reflect investors' perceptions of the future prospects and financial health of VistaGen Therapeutics, and VistaGen Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VistaGen Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (64.62) % | ||||
| Current Valuation | (6.61 M) | ||||
| Shares Outstanding | 28.86 M | ||||
| Price To Earning | (0.66) X | ||||
| Price To Book | 0.99 X | ||||
| Price To Sales | 115.37 X | ||||
| Revenue | 1.06 M | ||||
| Gross Profit | 698 K | ||||
| EBITDA | (32.45 M) | ||||
| Net Income | (29.36 M) | ||||
| Cash And Equivalents | 51.99 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 2.12 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 2.87 X | ||||
| Cash Flow From Operations | (25.81 M) | ||||
| Earnings Per Share | (1.48) X | ||||
| Market Capitalization | 80.53 M | ||||
| Total Asset | 123.65 M | ||||
| Retained Earnings | (356.21 M) | ||||
| Working Capital | 115.55 M | ||||
| Current Asset | 6.91 M | ||||
| Current Liabilities | 1.8 M | ||||
About VistaGen Therapeutics Performance
By examining VistaGen Therapeutics' fundamental ratios, stakeholders can obtain critical insights into VistaGen Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that VistaGen Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 829.89 | 737.69 | |
| Return On Tangible Assets | (4.08) | (4.28) | |
| Return On Capital Employed | 8.95 | 14.87 | |
| Return On Assets | (4.08) | (4.28) | |
| Return On Equity | 8.98 | 12.43 |
Things to note about VistaGen Therapeutics performance evaluation
Checking the ongoing alerts about VistaGen Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for VistaGen Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| VistaGen Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.06 M. Net Loss for the year was (29.36 M) with profit before overhead, payroll, taxes, and interest of 698 K. | |
| VistaGen Therapeutics currently holds about 51.99 M in cash with (25.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
| VistaGen Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Vistagen Therapeutics Stock Price Crosses Above 50-Day Moving Average - Heres Why - MarketBeat |
- Analyzing VistaGen Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VistaGen Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining VistaGen Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VistaGen Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VistaGen Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VistaGen Therapeutics' stock. These opinions can provide insight into VistaGen Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.